• FirefoxUpgrade to the new Firefox »
  •  Dow Down1.45% Nasdaq Down1.03%

    AstraZeneca PLC (AZN)

    -NYSE
    71.04 Down 0.85(1.18%) Jan 30, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    AstraZeneca PLC
    2 Kingdom Street
    London, W2 6BD
    United Kingdom - Map
    Phone: 44 20 7604 8000
    Fax: 44 20 7604 8151
    Website: http://www.astrazeneca.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:51,500

    Business Summary 

    AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on AstraZeneca PLC

    Key Executives 
     PayExercised
    Mr. Pascal Soriot , 56
    Chief Exec. Officer, Exec. Director and Member of Disclosure Committee
    5.04M0.00
    Mr. Marc Dunover , 63
    Chief Financial Officer and Exec. Director
    446.00K0.00
    Mr. David Smith , 50
    Exec. VP of Operations & Information Services
    N/AN/A
    Dr. Catherine Bonuccelli M.D.,
    VP of External Scientific Affairs
    N/AN/A
    Mr. Karl H ,
    Director of Investor Relations
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.